1. Home
  2. ZNB vs GOVX Comparison

ZNB vs GOVX Comparison

Compare ZNB & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zeta Network Group Class A Ordinary Shares

ZNB

Zeta Network Group Class A Ordinary Shares

N/A

Current Price

$0.43

Market Cap

2.8M

ML Signal

N/A

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

N/A

Current Price

$1.85

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZNB
GOVX
Founded
2002
2001
Country
China
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8M
3.0M
IPO Year
2018
1996

Fundamental Metrics

Financial Performance
Metric
ZNB
GOVX
Price
$0.43
$1.85
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $240.00
AVG Volume (30 Days)
★ 2.6M
286.6K
Earning Date
10-19-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,489,145.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.10
$0.11
52 Week High
$9.78
$1,002.75

Technical Indicators

Market Signals
Indicator
ZNB
GOVX
Relative Strength Index (RSI) 35.09 55.16
Support Level $0.22 $0.11
Resistance Level $1.93 $3.00
Average True Range (ATR) 0.21 0.31
MACD -0.01 0.30
Stochastic Oscillator 6.67 62.62

Price Performance

Historical Comparison
ZNB
GOVX

About ZNB Zeta Network Group Class A Ordinary Shares

Zeta Network Group consist principally of cryptocurrency mining. The company conducts business as two operating segments which comprise of consulting services and cryptocurrency mining. Majority of revenue comes from cryptocurrency mining segment.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Share on Social Networks: